Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification

Fineline Cube Jul 24, 2026
Company Drug

Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance

Fineline Cube Jul 24, 2026
Company Drug

Sinocelltech Wins NMPA Clearance for TriAb SCTB39G in Solid Tumors

Fineline Cube Jun 26, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received clearance from the National...

Company Drug

CARsgen’s Satri-cel NDA Accepted by China’s NMPA for Gastric Adenocarcinoma

Fineline Cube Jun 26, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the National Medical Products Administration (NMPA)...

Company Drug

Lepu Biopharma Gains EMA Approval for MRG003 HNSCC Clinical Trial

Fineline Cube Jun 26, 2025

China-based Lepu Biopharma Co., Ltd (HKG: 2157) announced that it has received approval from the...

Company Deals

RemeGen Inks Global Licensing Pact With Vor Biopharma for Telitacicept

Fineline Cube Jun 26, 2025

China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an exclusive licensing agreement with U.S.-based...

Company Drug

Angel Pharma Gains NMPA Approval for Soquelitinib in Atopic Dermatitis Trial

Fineline Cube Jun 26, 2025

China-based Angel Pharmaceuticals Ltd announced that it has received approval from the National Medical Products...

Company Drug

Biogen’s Phase I Results Highlight Salanersen’s Potential in Spinal Muscular Atrophy

Fineline Cube Jun 26, 2025

Biogen (NASDAQ: BIIB) announced this week topline results from the Phase I study of salanersen...

Company Deals Drug

Kymera and Sanofi Advance IRAK4 Program With Selection of KT-485 for Clinical Development

Fineline Cube Jun 26, 2025

US-based Kymera Therapeutics Inc. (NASDAQ: KYMR) announced updates to its IRAK4-targeted program collaboration with Sanofi....

Company Drug

LG Chem’s Cross-Linked Sodium Hyaluronate Gel Gains NMPA Approval for Midface Use

Fineline Cube Jun 26, 2025

South Korea’s LG Chem announced that its cross-linked sodium hyaluronate gel with lidocaine has received...

Company Deals

Porton Advanced Partners With EVA Pharma to Boost CAR-T Cell Therapy in MENA

Fineline Cube Jun 26, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. has entered into a...

Company Drug

Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis

Fineline Cube Jun 26, 2025

US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA)...

Company Deals

Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD

Fineline Cube Jun 26, 2025

US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and...

Company Drug

SineuGene’s ALS Gene Therapy SNUG01 Granted FDA Orphan Drug Designation

Fineline Cube Jun 26, 2025

Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced this week that...

Company Drug

Acotec Scientific Wins NMPA Approval for Armoni-HP Balloon Catheter

Fineline Cube Jun 26, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Oncolytic Immunotherapy Pipeline

Fineline Cube Jun 26, 2025

Shenzhen-based Immvira Bioscience Inc. has filed for an initial public offering (IPO) with the Hong...

Company Drug

Genevector’s JWK002 Gains NMPA IND Approval for XLRS Gene Therapy

Fineline Cube Jun 26, 2025

China-based Chengdu Geneector Biotechnology Co., Ltd. (Genevector), a developer of AAV gene therapy drugs, announced...

Company Deals

CMS Plans Secondary Listing on Singapore Exchange to Enhance Shareholder Base and Liquidity

Fineline Cube Jun 25, 2025

China Medical System Holdings Ltd (CMS; HKG: 0867) announced its proposal for a secondary listing...

Company Drug

Livzon’s YJH-012 siRNA Drug Gets NMPA Green Light for Gout Trials

Fineline Cube Jun 25, 2025

China-based Livzon Pharmaceutical Group Inc., (HKG: 1513) announced that its Category 1 chemical drug YJH-012...

Company Medical Device

GE Healthcare Wins FDA Approval for Vizamyl Label Update in Alzheimer’s Detection

Fineline Cube Jun 25, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc., (NASDAQ: GEHC) announced that...

Policy / Regulatory

NHSA Emphasizes Management of Designated Medical Institutions for Healthcare Quality

Fineline Cube Jun 25, 2025

The National Healthcare Security Administration (NHSA) this week released a notification emphasizing the importance of...

Company Deals

Suzhou Porton Biologics Partners with Future Biotechnology to Expand Viral Vector Services

Fineline Cube Jun 25, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd announced this week a...

Posts pagination

1 … 170 171 172 … 699

Recent updates

  • Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification
  • Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance
  • Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136
  • Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market
  • Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification

Company Drug

Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance

Company Drug

Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136

Company Drug

Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.